Hirudins and fenestrins of the African medicinal leech Asiaticobdella fenestrata
Schulz L, Tolksdorf C, Rauch BH, Kvist S, Müller C (2025) · Parasitology Research · n=0
Study Profile
- Design
- comparative salivary gland transcriptome analysis of African medicinal leech Asiaticobdella fenestrata with recombinant protein expression and functional characterization
- Sample size (n)
- 0
- Intervention
- Identification of two putative hirudins and two novel RGD-motif platelet aggregation inhibitors ("fenestrins") from A. fenestrata salivary glands
- Comparator
- Established hirudin and decorsin/ornatin sequences from European medicinal leech (Hirudo medicinalis)
- Primary endpoint
- Structural and functional characterization of novel bioactive compounds in coagulation and platelet aggregation assays
- Primary result
- Two putative hirudins and two novel "fenestrins" (RGD-motif platelet aggregation inhibitors with unique N-terminal location) functionally characterized; demonstrates African leech species as untapped source of bioactive anticoagulant inspiration
- Follow-up duration
- Laboratory characterization phase
- PMID
- 41198932
Key Findings
- Two novel hirudin-like factors with unique N-terminal RGD motif
- Two new platelet aggregation inhibitors named "fenestrins"
- Distinct from European hirudin/decorsin structural patterns
- Recombinant expression and functional characterization completed
- Extends understanding of leech biodiversity beyond H. medicinalis
Limitations
- Preclinical characterization only - no clinical application yet
- Limited to A. fenestrata species
- RGD motif location significance not fully elucidated
- Functional assays in vitro only
- No bridge to clinical use established
Clinical Implications
Schulz 2025 expands the leech bioactive compound landscape by characterizing novel hirudins and fenestrins from the African medicinal leech Asiaticobdella fenestrata. For ASH, this preclinical work extends the species and compound diversity beyond European Hirudo medicinalis (the K040187-cleared species), informing future drug development for synthetic recombinant anticoagulants distinct from device-leech practice.
Related Trials
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)
Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)